Vasileios Karantalis1, Darcy L DiFede, Gary Gerstenblith, Si Pham, James Symes, Juan Pablo Zambrano, Joel Fishman, Pradip Pattany, Ian McNiece, John Conte, Steven Schulman, Katherine Wu, Ashish Shah, Elayne Breton, Janice Davis-Sproul, Richard Schwarz, Gary Feigenbaum, Muzammil Mushtaq, Viky Y Suncion, Albert C Lardo, Ivan Borrello, Adam Mendizabal, Tomer Z Karas, John Byrnes, Maureen Lowery, Alan W Heldman, Joshua M Hare. 1. From the University of Miami Miller School of Medicine, Interdisciplinary Stem Cell Institute, Miami, FL (V.K., D.L.D., R.S., M.M., V.Y.S., A.W.L., J.M.H.); Johns Hopkins University, Cardiovascular Division, Baltimore, MD (G.G., S.S., E.B., J.D.-S., A.C.L.); University of Maryland, Cardiothoracic Surgery, Baltimore, MD (S.P., J.C.); Veterans Affairs Healthcare System, Cardiothoracic Surgery, Miami, FL (J.S., T.Z.K.); Jackson Health System, Cardiology, Miami, FL (J.P.Z.); University of Miami Miller School of Medicine, Radiology, Miami, FL (J.F., P.P.); University of Texas MD Anderson, Stem Cell Transplantation, Houston, TX (I.M.N.), Johns Hopkins University, Heart and Vascular Institute, Baltimore, MD (K.W.), Johns Hopkins University, Comprehensive Transplant Center (A.S.); University of Southern California, Internal Medicine, Los Angeles, CA (G.F.); Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD (I.B.); EMMES Corporation, Rockville, MD (A.M.), University of Miami Miller School of Medicine, Hematology/Oncology, Miami, FL (J.B.); and University of Miami Miller School of Medicine, Cardiology, Miami, FL (T.Z.K., M.L.).
Abstract
RATIONALE: Although accumulating data support the efficacy of intramyocardial cell-based therapy to improve left ventricular (LV) function in patients with chronic ischemic cardiomyopathy undergoing CABG, the underlying mechanism and impact of cell injection site remain controversial. Mesenchymal stem cells (MSCs) improve LV structure and function through several effects including reducing fibrosis, neoangiogenesis, and neomyogenesis. OBJECTIVE: To test the hypothesis that the impact on cardiac structure and function after intramyocardial injections of autologous MSCs results from a concordance of prorecovery phenotypic effects. METHODS AND RESULTS: Six patients were injected with autologous MSCs into akinetic/hypokinetic myocardial territories not receiving bypass graft for clinical reasons. MRI was used to measure scar, perfusion, wall thickness, and contractility at baseline, at 3, 6, and 18 months and to compare structural and functional recovery in regions that received MSC injections alone, revascularization alone, or neither. A composite score of MRI variables was used to assess concordance of antifibrotic effects, perfusion, and contraction at different regions. After 18 months, subjects receiving MSCs exhibited increased LV ejection fraction (+9.4 ± 1.7%, P=0.0002) and decreased scar mass (-47.5 ± 8.1%; P<0.0001) compared with baseline. MSC-injected segments had concordant reduction in scar size, perfusion, and contractile improvement (concordant score: 2.93 ± 0.07), whereas revascularized (0.5 ± 0.21) and nontreated segments (-0.07 ± 0.34) demonstrated nonconcordant changes (P<0.0001 versus injected segments). CONCLUSIONS: Intramyocardial injection of autologous MSCs into akinetic yet nonrevascularized segments produces comprehensive regional functional restitution, which in turn drives improvement in global LV function. These findings, although inconclusive because of lack of placebo group, have important therapeutic and mechanistic hypothesis-generating implications. CLINICAL TRIAL REGISTRATION URL: http://clinicaltrials.gov/show/NCT00587990. Unique identifier: NCT00587990.
RCT Entities:
RATIONALE: Although accumulating data support the efficacy of intramyocardial cell-based therapy to improve left ventricular (LV) function in patients with chronic ischemic cardiomyopathy undergoing CABG, the underlying mechanism and impact of cell injection site remain controversial. Mesenchymal stem cells (MSCs) improve LV structure and function through several effects including reducing fibrosis, neoangiogenesis, and neomyogenesis. OBJECTIVE: To test the hypothesis that the impact on cardiac structure and function after intramyocardial injections of autologous MSCs results from a concordance of prorecovery phenotypic effects. METHODS AND RESULTS: Six patients were injected with autologous MSCs into akinetic/hypokinetic myocardial territories not receiving bypass graft for clinical reasons. MRI was used to measure scar, perfusion, wall thickness, and contractility at baseline, at 3, 6, and 18 months and to compare structural and functional recovery in regions that received MSC injections alone, revascularization alone, or neither. A composite score of MRI variables was used to assess concordance of antifibrotic effects, perfusion, and contraction at different regions. After 18 months, subjects receiving MSCs exhibited increased LV ejection fraction (+9.4 ± 1.7%, P=0.0002) and decreased scar mass (-47.5 ± 8.1%; P<0.0001) compared with baseline. MSC-injected segments had concordant reduction in scar size, perfusion, and contractile improvement (concordant score: 2.93 ± 0.07), whereas revascularized (0.5 ± 0.21) and nontreated segments (-0.07 ± 0.34) demonstrated nonconcordant changes (P<0.0001 versus injected segments). CONCLUSIONS: Intramyocardial injection of autologous MSCs into akinetic yet nonrevascularized segments produces comprehensive regional functional restitution, which in turn drives improvement in global LV function. These findings, although inconclusive because of lack of placebo group, have important therapeutic and mechanistic hypothesis-generating implications. CLINICAL TRIAL REGISTRATION URL: http://clinicaltrials.gov/show/NCT00587990. Unique identifier: NCT00587990.
Authors: Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare Journal: Circ Res Date: 2010-07-29 Impact factor: 17.367
Authors: Adam R Williams; Barry Trachtenberg; Darcy L Velazquez; Ian McNiece; Peter Altman; Didier Rouy; Adam M Mendizabal; Pradip M Pattany; Gustavo A Lopera; Joel Fishman; Juan P Zambrano; Alan W Heldman; Joshua M Hare Journal: Circ Res Date: 2011-03-17 Impact factor: 17.367
Authors: Clerio F Azevedo; Luciano C Amado; Dara L Kraitchman; Bernhard L Gerber; Nael F Osman; Carlos E Rochitte; Thor Edvardsen; Joao A C Lima Journal: Eur Heart J Date: 2004-08 Impact factor: 29.983
Authors: Shwetha Mureli; Christopher P Gans; Dan J Bare; David L Geenen; Nalin M Kumar; Kathrin Banach Journal: Am J Physiol Heart Circ Physiol Date: 2012-12-15 Impact factor: 4.733
Authors: Gerald S Werner; Ulf Emig; Oliver Mutschke; Gero Schwarz; Philipp Bahrmann; Hans R Figulla Journal: Circulation Date: 2003-11-17 Impact factor: 29.690
Authors: Alan W Heldman; Darcy L DiFede; Joel E Fishman; Juan P Zambrano; Barry H Trachtenberg; Vasileios Karantalis; Muzammil Mushtaq; Adam R Williams; Viky Y Suncion; Ian K McNiece; Eduard Ghersin; Victor Soto; Gustavo Lopera; Roberto Miki; Howard Willens; Robert Hendel; Raul Mitrani; Pradip Pattany; Gary Feigenbaum; Behzad Oskouei; John Byrnes; Maureen H Lowery; Julio Sierra; Mariesty V Pujol; Cindy Delgado; Phillip J Gonzalez; Jose E Rodriguez; Luiza Lima Bagno; Didier Rouy; Peter Altman; Cheryl Wong Po Foo; Jose da Silva; Erica Anderson; Richard Schwarz; Adam Mendizabal; Joshua M Hare Journal: JAMA Date: 2014-01-01 Impact factor: 56.272
Authors: Adam R Williams; Viky Y Suncion; Frederic McCall; Danny Guerra; Jacques Mather; Juan P Zambrano; Alan W Heldman; Joshua M Hare Journal: J Am Heart Assoc Date: 2013-05-17 Impact factor: 5.501
Authors: Joshua Mayourian; Delaine K Ceholski; David M Gonzalez; Timothy J Cashman; Susmita Sahoo; Roger J Hajjar; Kevin D Costa Journal: Circ Res Date: 2018-01-05 Impact factor: 17.367
Authors: Vincenzo Grimaldi; Alberto Zullo; Francesco Donatelli; Francesco Paolo Mancini; Francesco Cacciatore; Claudio Napoli Journal: J Thorac Dis Date: 2018-07 Impact factor: 2.895